FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Street) BETHESDA	MD	20814		X Form filed by One Reporting Person Form filed by More than One Reporting Person
4550 MONTGOMERY AVE. SUITE 1100N			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/15/2024	Officer (give title Other (specify below) below)
	ess of Reporting Per sis Foundation		2. Issuer Name and Ticker or Trading Symbol BiomX Inc. [PHGE]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)		4. Securities Ac Disposed Of (D)			Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(instr. 4)
Common Stock, par value \$0.0001 per share	05/15/2024		х		4,778,265	Α	\$0.001	9,330,580	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transac Code (In 8)		Deriv Secur Acqui Dispo		6. Date Exerce Expiration Da (Month/Day/N	ate	7. Title and A Securities Ur Derivative Se 3 and 4)	derlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Warrant to purchase common stock	\$0.001	05/15/2024	x			4,778,265	(1)	(1)	Common stock	4,778,265	\$0	0	D	

Explanation of Responses:

1. The warrant was exercisable beginning on February 27, 2023, for that number of shares that would not result in the Reporting Person beneficially owning more than 9.99% of the number of shares of common stock then issued and outstanding upon such exercise, and became exercisable in full on May 15, 2024. The warrant does not expire.

<u>/s/ Ania Howell</u>						
** **			-			

Signature of Reporting Person

05/17/2024 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.